Gurudatt Chandorkar - Concepedia

Author

Gurudatt Chandorkar

Cubist Pharmaceuticals (United States)

Also Known As

G CHANDORKAR, G. Chandorkar, Gurudatt A Chandorkar, Gurudatt A. Chandorkar, Gurudatt Chandorkar

Publications

974

Citations

H-Index

Concepts

All Affiliations

Cubist Pharmaceuticals (United States)Vertex Pharmaceuticals (United States)University of Kansas

About

Gurudatt Chandorkar is an author at Cubist Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	312
2	Health Sciences	1	1	16
3	Natural Sciences	1	1	75
4	Biochemistry	1	1	75
5	Biomolecular Engineering	1	1	17

Gurudatt Chandorkar

Publications

973

Citations

H-Index

Page 1

	Year	Citations
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease Robert B. Perni, Susan J. Almquist, Randal A. Byrn, Antimicrobial Agents and Chemotherapy	2006	382
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects Gurudatt Chandorkar, Jennifer A. Huntington, Mark H. Gotfried, Journal of Antimicrobial Chemotherapy	2012	118
Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells☆ Naoki Utoguchi, Gurudatt Chandorkar, Michael L. Avery, Reproductive Toxicology Bewo Cells☆Protein ExpressionCellular EnzymologyBiochemistryNatural Sciences	2000	75
Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam Myra Wooley, Benjamin Miller, Gopal Krishna, Antimicrobial Agents and Chemotherapy	2014	72
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections Gurudatt Chandorkar, Alan Xiao, Samer Mouksassi, The Journal of Clinical Pharmacology PharmacotherapyAntimicrobial ChemotherapyPopulation PharmacokineticsPharmacodynamic ModelingRenal Function	2014	63
Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin Varun Garg, Gurudatt Chandorkar, Hayley Farmer, The Journal of Clinical Pharmacology Therapeutic Drug MonitoringTranslational MedicineIv MidazolamPharmacologyPharmacotherapy	2011	61
Single-dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-positive Infections Susan M. Abdel‐Rahman, Gurudatt Chandorkar, Ronda L. Akins, The Pediatric Infectious Disease Journal Antibiotic AdjuvantDaptomycin 8PharmacotherapyAntimicrobial ChemotherapyPharmacokinetic Analysis	2011	52
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers Varun Garg, Gurudatt Chandorkar, Yijun Yang, British Journal of Clinical Pharmacology	2012	40
Transport and metabolism of opioid peptides across BeWo cells, an in vitro model of the placental barrier Chadarat Ampasavate, Gurudatt Chandorkar, David G Vande Velde, International Journal of Pharmaceutics NeuropeptidesGastrointestinal Peptide HormoneMedicinePhysiologyPlacental Barrier	2002	28
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders†‡ Vinod K. Rustgi, William M. Lee, Eric Lawitz, Hepatology	2009	23

Page 1